Does Wegovy reduce blood pressure — and by how much?

What the STEP 1 trial actually found about blood pressure

The pivotal STEP 1 trial, published in the New England Journal of Medicine, enrolled 1,961 adults with obesity or overweight and at least one weight-related condition, without type 2 diabetes. Over 68 weeks, participants taking semaglutide 2.4mg lost an average of around 15% of their body weight. Alongside that, systolic blood pressure fell by roughly 4–6 mmHg more than in the placebo group, a modest but real difference at a population level. Diastolic pressure also improved, though the effect was smaller.

Four to six mmHg may sound unremarkable, but epidemiological data consistently show that a sustained 5 mmHg reduction in systolic pressure is associated with meaningfully lower stroke and heart-attack risk across large populations. For someone starting at 145 mmHg, reaching 139–140 mmHg matters. For someone already well controlled on medication, the picture is more nuanced, and worth discussing with a prescriber rather than assuming treatment will amplify their existing drugs' effects.

The cardiovascular signal in semaglutide's trial programme goes further than blood pressure alone. The SELECT trial found that semaglutide 2.4mg reduced the rate of major adverse cardiovascular events in adults with established cardiovascular disease and obesity. This broader evidence base contributed to the MHRA authorising a separate cardiovascular-risk indication for Wegovy, distinct from its weight-management licence. If you are wondering whether Wegovy helps blood pressure and how the evidence stacks up, that page examines the question in detail, including what the cardiovascular-outcomes data mean in practice. If you want to explore the full picture of how Wegovy affects blood pressure markers, that covers the cardiovascular-outcomes data in more depth.

Why weight loss and blood pressure are so closely linked

The blood pressure reduction seen with semaglutide is not mainly a direct drug effect on vascular tone. It appears to follow weight loss. Adipose tissue, particularly visceral fat around the organs, raises blood pressure through several mechanisms: increased circulating volume, activation of the renin–angiotensin–aldosterone system, raised sympathetic nervous activity, and low-grade systemic inflammation. When weight falls, many of those pathways settle down.

This means the blood pressure benefit scales with how much weight is lost. Someone losing 20% of their body weight is likely to see a larger reduction than someone who loses 8%. It also means the benefit requires sustained weight loss, if treatment stops and weight returns, blood pressure tends to follow. The NHS medicines page for semaglutide notes that Wegovy is intended to be used alongside a reduced-calorie diet and increased physical activity for precisely this reason: lifestyle changes reinforce and extend the physiological gains.

People already taking antihypertensive medicines should tell their prescriber before starting Wegovy. As weight falls and blood pressure drops, existing medication doses may need reviewing, occasionally, people find their antihypertensive needs adjusting downward. That is a good problem to have, but it needs clinical oversight rather than self-management. Our frequently asked questions cover some of the practical queries about starting Wegovy alongside existing medicines.

High blood pressure as a qualifying condition for Wegovy

Hypertension is one of the weight-related conditions that can make adults with a BMI of 27–29.9 eligible for Wegovy under its UK licence, alongside conditions such as dyslipidaemia, type 2 diabetes, obstructive sleep apnoea, and cardiovascular disease. People with a BMI of 30 or above may be eligible regardless of whether a comorbidity is present, though a prescriber assesses the full clinical picture before any decision is made. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance.

This eligibility framing matters for a practical reason. If your GP has noted high blood pressure on your records and your BMI sits in the 27–29.9 range, that combination may open the door to treatment that tackles both the underlying weight and the cardiovascular risk simultaneously, rather than adding a second pill to an existing one. If you want to understand how Wegovy and blood pressure interact across different patient profiles, that page is worth reading if this describes your situation.

On the NHS, Wegovy is recommended by NICE (TA875) only within specialist weight management services, and waiting lists are commonly long. Private treatment through a regulated online pharmacy is the alternative for people who meet the clinical criteria but cannot access NHS services quickly. For context on what private treatment costs, the Wegovy cost page sets out what an honest transparent price includes (consultation, prescription, aftercare, and tracked next-working-day delivery) and what headline prices elsewhere sometimes leave out.

Practical points your prescriber will want to know

If blood pressure is part of your reason for considering Wegovy, arrive at your consultation with recent readings if you have them. Home blood pressure monitors are now accurate and inexpensive, and a log of readings over two or three weeks gives a prescriber far more useful information than a single surgery reading taken after climbing three flights of stairs. Your GP's records, your current medications, and any previous diagnosis of kidney disease or heart conditions are all relevant.

A prescriber at a clinician-led service like ours reviews your answers personally, not algorithmically, before any prescription is issued. If Wegovy is clinically appropriate and approved, treatment arrives by DPD the next working day in plain, unbranded packaging, you can track it to your door. Once on treatment, your blood pressure is worth monitoring regularly, particularly in the first few months when weight loss is fastest and the effect on blood pressure most active. The semaglutide overview covers the broader clinical profile, including the side effects to watch for and when to contact a prescriber promptly.

Wegovy is not classified as a blood-pressure medicine, and it should not be used as a substitute for antihypertensive therapy in people who need it. What it can do, for the right person, is address the weight that is making hypertension harder to control, and that is a meaningful clinical contribution. Those considering Wegovy after pregnancy can find guidance on using Wegovy in the postpartum period, including how eligibility and safety considerations apply after giving birth. If you think you might be a suitable candidate, checking your eligibility with our prescribers is the logical next step.